Test Code: 4970

BEST1-related Disorders: BEST1 Gene Deletion/Duplication
Test Code: 4970
Turnaround time: 3 weeks


Pathogenic variants in the BEST1 gene (11q12), also known as VMD2, have been associated with several ocular phenotypes. The BEST1 gene encodes the bestrophin-1 protein, which is expressed in the retinal pigment epithelium and has also been detected in the kidney, brain, spinal cord, and testis. The most common BEST1-related disorder is best vitelliform macular dystrophy (BVMD). Pathogenic variants in the BEST1 gene cause several clinically distinct disorders.

Best Vitelliform Macular Dystrophy (BVMD)
BVMD is a slowly progressive macular dystrophy that is inherited in an autosomal dominant manner. Onset is typically in childhood. Individuals with BVMD present with decreased central visual acuity and metamorphopsia. They retain normal dark adaptation and peripheral vision. Inter- and intrafamilial variability is seen regarding severity of vision loss and age of onset. The abnormalities observed in BVMD are restricted to the macula.

Autosomal Dominant Vitreoretinochoroidopathy (ADVIRC)
ADVIRC is characterized by a peripheral circumferential retinal band of pigmentary alterations, fibrillary vitreous condensations, punctate white pre or intraretinal deposits, and midperipheral and peripapillary chorioretinal atrophy. Most individuals with ADVIRC retain a fairly good visual acuity throughout life. Additional features include congenital or early-onset cataracts, microcornea, hypermetrophic, and shallow anterior chamber.

Autosomal Recessive Bestrophinopathy (ARB)
Two pathogenic variants in BEST1 cause the clinically distinct autosomal recessive ARB, which is characterized by central visual loss and hyperopia. The age of onset ranges from 4 to 40 years of age with the average being in the 20s.

Other rare clinical presentations associated with pathogenic variants in BEST1 have also been described.


  • GeneReviews
  • OMIM #607852: BEST1 gene
  • Boon et al. (2009), Prog Retin Eye Res, 28:187-205. Davidson et al. (2009), Am J Hum Genet, 85:581-592.


This test is indicated for:

  • Confirmation of a clinical diagnosis of a BEST1-related disorder in an individual in whom sequence analysis was negative.
  • Carrier testing in adults with a family history of a BEST1-related disorder in whom sequence analysis was negative.


DNA isolated from peripheral blood is hybridized to a CGH array to detect deletions and duplications. The targeted CGH array has overlapping probes which cover the entire genomic region.

Please note that a “backbone” of probes across the entire genome are included on the array for analytical and quality control purposes. Rarely, off- target copy number variants causative of disease may be identified that may or may not be related to the patient’s phenotype. Only known pathogenic off-target copy number variants will be reported. Off-target copy number variants of unknown clinical significance will not be reported.


Detection is limited to duplications and deletions. The CGH array will not detect point or intronic mutations. Results of molecular analysis must be interpreted in the context of the patient’s clinical and/or biochemical phenotype.


Type: Whole Blood
Specimen Requirements:
In EDTA (purple top) or ACD (yellow top) tube: Infants (2 years): 3-5 ml Older Children & Adults: 5-10 ml

Specimen Collection and Shipping: Store sample at room temperature. Ship sample within 5 days of collection at room temperature with overnight delivery.

Type: Saliva
Specimen Requirements:
OrageneTM Saliva Collection kit (available through CEN4GEN) used according to manufacturer instructions.

Specimen Collection and Shipping: Please do not refrigerate or freeze saliva sample. Please store and ship at room temperature.


Sequence analysis is required before deletion/duplication analysis by targeted CGH array. If sequencing is performed by another third party provider, please submit a copy of the sequencing report with the test requisition.


  • Sequence analysis of the BEST1 gene is available and is required before deletion/duplication analysis.
  • Several comprehensive next generation sequencing Eye Disorder Panels are available.
  • Custom diagnostic mutation analysis (test code: 6875) is available to family members if mutations are identified by targeted mutation testing or sequencing analysis.